Here are five facts:
1. One analyst gave the shares an “outperform” rating and two analysts gave the shares a “hold” rating.
2. No analysts rated the shares as “underperform” or “sell.”
3. Northland Securities reiterated Exactech shares’ “market perform” rating on Oct. 28, 2015.
4. Exactech has a 50-day moving average of $18.79 and a 200-day moving average of $18.32.
5. The market cap is nearly $281.4 million.
More articles on devices:
Beyond the device: How DePuy Synthes is innovating in orthopedic & spine technology
UW Medicine’s orthopedics & urology departments to implement C-SATS — 5 things to know
LDR, Xtant Medical, Smith & Nephew & more: 14 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
